loading page

Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
  • +2
  • Isaac Hauk,
  • Ignacio Gonzalez-Gomez,
  • Deepak Chellapandian,
  • Jonathan Metts,
  • Peter Shaw
Isaac Hauk
Johns Hopkins All Children's Hospital
Author Profile
Ignacio Gonzalez-Gomez
Johns Hopkins All Children's Hospital
Author Profile
Deepak Chellapandian
Johns Hopkins All Children's Hospital
Author Profile
Jonathan Metts
Moffitt Cancer Center
Author Profile
Peter Shaw
Milwaukee Hospital-Children's Wisconsin

Corresponding Author:pshaw@mcw.edu

Author Profile

Abstract

Juvenile xanthogranuloma (JXG) is a clonal non-Langerhans cell histiocytic disorder characterized by a variety of cutaneous and non-cutaneous manifestations, predominantly in children. The mitogen-activated protein kinase pathway (MAPK) is a key driver in many histiocytic disorders, including JXG. We report a rare presentation of JXG in the mastoid bone of a which recurred after surgery and was refractory to two lines of chemotherapy before responding to the MEK inhibitor trametinib, even in the absence of an identifiable MAPK pathway mutation. MEK inhibitors may be a therapeutic option for this sometimes difficult to treat disease.
Submitted to Pediatric Blood & Cancer
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned